D.G. McGowan

2.1k total citations · 1 hit paper
26 papers, 1.5k citations indexed

About

D.G. McGowan is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Surgery. According to data from OpenAlex, D.G. McGowan has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 7 papers in Rheumatology and 6 papers in Surgery. Recurrent topics in D.G. McGowan's work include Prostate Cancer Treatment and Research (19 papers), Prostate Cancer Diagnosis and Treatment (16 papers) and Urologic and reproductive health conditions (7 papers). D.G. McGowan is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Prostate Cancer Diagnosis and Treatment (16 papers) and Urologic and reproductive health conditions (7 papers). D.G. McGowan collaborates with scholars based in Canada, United States and India. D.G. McGowan's co-authors include Howard M. Sandler, Luís Souhami, Mark H. Leibenhaut, Marvin Rotman, William U. Shipley, Christopher U. Jones, Daniel Hunt, Siraj Husain, Mahul B. Amin and Deborah Watkins Bruner and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

D.G. McGowan

26 papers receiving 1.5k citations

Hit Papers

Radiotherapy and Short-Term Androgen Deprivation for Loca... 2011 2026 2016 2021 2011 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
    2011 473 citations Christopher U. Jones, Daniel Hunt et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D.G. McGowan Canada 16 1.2k 416 356 319 261 26 1.5k
Ignace Billiet Belgium 13 1.7k 1.4× 443 1.1× 283 0.8× 575 1.8× 376 1.4× 37 2.1k
S. Guérif France 16 1.0k 0.9× 237 0.6× 375 1.1× 200 0.6× 465 1.8× 65 1.5k
Harvey B. Wolkov United States 14 1.4k 1.2× 366 0.9× 313 0.9× 105 0.3× 330 1.3× 22 1.7k
Chris Atkinson New Zealand 15 1.0k 0.9× 178 0.4× 197 0.6× 154 0.5× 312 1.2× 27 1.3k
Arne Solberg Norway 14 978 0.8× 636 1.5× 214 0.6× 174 0.5× 181 0.7× 34 1.4k
Scott C. Morgan Canada 19 1.2k 1.0× 308 0.7× 305 0.9× 337 1.1× 389 1.5× 100 1.7k
Paul Van Cangh Belgium 13 1.5k 1.2× 418 1.0× 158 0.4× 111 0.3× 352 1.3× 34 2.0k
Kerri Cote United States 16 1.0k 0.8× 215 0.5× 158 0.4× 157 0.5× 164 0.6× 22 1.2k
Hedy Mameghan Australia 20 602 0.5× 415 1.0× 254 0.7× 192 0.6× 198 0.8× 54 1.2k
K. Vekemans Belgium 14 1.9k 1.6× 318 0.8× 214 0.6× 169 0.5× 536 2.1× 24 2.1k

Countries citing papers authored by D.G. McGowan

Since Specialization
Citations

This map shows the geographic impact of D.G. McGowan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.G. McGowan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.G. McGowan more than expected).

Fields of papers citing papers by D.G. McGowan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.G. McGowan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.G. McGowan. The network helps show where D.G. McGowan may publish in the future.

Co-authorship network of co-authors of D.G. McGowan

This figure shows the co-authorship network connecting the top 25 collaborators of D.G. McGowan. A scholar is included among the top collaborators of D.G. McGowan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.G. McGowan. D.G. McGowan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hallemeier, Christopher L., Peixin Zhang, Thomas M. Pisansky, et al.. (2019). Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. International Journal of Radiation Oncology*Biology*Physics. 104(5). 1057–1065. 7 indexed citations
2.
Nichols, R.C., Chen Hu, Jean-Paul Bahary, et al.. (2017). Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408. Advances in Radiation Oncology. 2(4). 608–614. 13 indexed citations
3.
Krauss, Daniel, Chen Hu, Jean-Paul Bahary, et al.. (2015). Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. International Journal of Radiation Oncology*Biology*Physics. 92(4). 863–873. 22 indexed citations
4.
Paulus, Rebecca, William U. Shipley, Matthew R. Smith, et al.. (2015). Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. European Urology. 69(2). 204–210. 32 indexed citations
5.
Krauss, Daniel, Daniel Hunt, J.P. Bahary, et al.. (2013). Inferior Clinical Outcomes for Patients With Positive Post-Radiation Therapy Prostate Biopsy: Results From Prospective Randomized Trial RTOG 94-08. International Journal of Radiation Oncology*Biology*Physics. 87(2). S23–S23. 1 indexed citations
6.
Hamstra, Daniel A., Kyounghwa Bae, Miljenko V. Pilepich, et al.. (2011). Older Age Predicts Decreased Metastasis and Prostate Cancer-Specific Death for Men Treated With Radiation Therapy: Meta-Analysis of Radiation Therapy Oncology Group Trials. International Journal of Radiation Oncology*Biology*Physics. 81(5). 1293–1301. 38 indexed citations
7.
Jones, Christopher U., Daniel Hunt, D.G. McGowan, et al.. (2011). Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer. New England Journal of Medicine. 365(2). 107–118. 473 indexed citations breakdown →
8.
McGowan, D.G., C.A. Lawton, G. Hanks, et al.. (1998). Validation of the sexual adjustment questionnaire (SAQ) in prostate cancer patients enrolled on radiation therapy oncology group (RTOG) studies 90-20 and 94-08. International Journal of Radiation Oncology*Biology*Physics. 42(1). 202–202. 14 indexed citations
9.
Lawton, C.A., Kathryn Winter, Roger W. Byhardt, et al.. (1997). Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). International Journal of Radiation Oncology*Biology*Physics. 38(5). 931–939. 66 indexed citations
10.
Regunathan, S., et al.. (1997). An antiserum to idazoxan recognizes an immunoreactive substance in human serum and cerebral spinal fluid which is not agmatine. Neurochemistry International. 30(1). 85–94. 7 indexed citations
11.
Pilepich, Miljenko V., Jan W. Buzydlowski, Madhu J. John, et al.. (1995). Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: Outcome results of RTOG 83-07. International Journal of Radiation Oncology*Biology*Physics. 32(1). 175–180. 24 indexed citations
12.
McEwan, Alexander, et al.. (1994). A retrospective analysis of the cost effectiveness of treatment with Metastron?? (89Sr-chloride) in patients with prostate cancer metastatic to bone. Nuclear Medicine Communications. 15(7). 499–504???504. 47 indexed citations
13.
Amyotte, G., et al.. (1994). A Retrospective Analysis of theCost Effectiveness of Treatmentwith Metastron in Patients withProstate Cancer Metastatic toBone. European Urology. 26(1). 26–31. 33 indexed citations
14.
Porter, Arthur T., Alexander McEwan, John Powe, et al.. (1993). Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 25(5). 805–813. 379 indexed citations
15.
McGowan, D.G.. (1988). The effect of transurethral resection on prognosis in carcinoma of the prostate: real or imaginary?. International Journal of Radiation Oncology*Biology*Physics. 15(5). 1057–1064. 10 indexed citations
16.
McGowan, D.G., et al.. (1987). The Usefulness of Gallium-67 Citrate Scanning in Testicular Seminoma. Clinical Nuclear Medicine. 12(10). 813–815. 9 indexed citations
17.
McGowan, D.G.. (1981). The value of extended field radiation therapy in carcinoma of the prostate. International Journal of Radiation Oncology*Biology*Physics. 7(10). 1333–1339. 78 indexed citations
18.
McGowan, D.G.. (1980). The adverse influence of prior transurethral resection on prognosis in carcinoma of prostate treated by radiation therapy. International Journal of Radiation Oncology*Biology*Physics. 6(9). 1121–1126. 70 indexed citations
19.
McGowan, D.G.. (1977). Rdiation therapy in the management of localized carcinoma of the prostate.A preliminary report. Cancer. 39(1). 98–103. 44 indexed citations
20.
Lentle, Brian C., et al.. (1974). Technetium‐99M Polyphosphate Bone Scanning in Carcinoma of the Prostate. British Journal of Urology. 46(5). 543–548. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ignace Billiet Breakdown of academic impact, for papers by S. Guérif Breakdown of academic impact, for papers by Harvey B. Wolkov Breakdown of academic impact, for papers by Chris Atkinson Breakdown of academic impact, for papers by Arne Solberg Breakdown of academic impact, for papers by Scott C. Morgan Breakdown of academic impact, for papers by Paul Van Cangh Breakdown of academic impact, for papers by Kerri Cote Breakdown of academic impact, for papers by Hedy Mameghan Breakdown of academic impact, for papers by K. Vekemans
Rankless by CCL
2026